UBS initiates Chemed stock coverage with buy rating on growth outlook
UBS initiated coverage on Chemed Corp. (NYSE: CHE) with a buy rating and a $650 price target, citing low double-digit EPS growth outlook. The stock trades at $495.65, below UBS's fair value estimate of $570.59. Chemed reported strong Q2 earnings, exceeding expectations, driven by growth in its VITAS hospice unit and steady Roto-Rooter results. The company raised its outlook, highlighting improved operating leverage.
How this was made
The 30-second read
Why it matters
The combination of a buy rating, a $650 price target, and strong earnings may drive short-term buying interest.
Market read
Chemed's strong earnings and upgraded analyst coverage could boost its stock and influence sector sentiment.
What to watch
Potential regulatory risks in hospice care and competitive pressure on Roto-Rooter are not addressed.
Background
UBS coverage initiation and Q2 earnings beat provide fresh analyst perspective on Chemed Corp.
Ticker impact
UBS initiated coverage on Chemed Corp. with a buy rating and a $650 price target, and reported the company's Q2 earnings beat expectations.
Potential price appreciation toward the $650 target.
Buy rating and price target raise, combined with 41.9% YoY EPS growth, indicate bullish sentiment.
Market effects
Positive outlook for home health and plumbing services may lift peers in the healthcare services sector.
Limited to US markets where Chemed trades.
Minimal global impact beyond sector peers.
Counterpoint
The high valuation multiples could be stretched if growth slows, making the $650 target optimistic.
Key entities
- CompanyChemed Corp.
Provider of hospice and home health services and plumbing services.
- AnalystUBS
Investment bank that initiated coverage with a buy rating.
